The biotechnology of Sydney Noxopharm says that a clinical trial suggests that its radiation sensitizing suppository was able to extend the average lifespan of 32 men with terminal prostate cancer.
The men were treated with Veyonda in combination with the experimental radioactive drug of Novartis $ 6 billion 177Lu-PSMA-617 at St Vincent Hospital in Sydney after at least two and in most cases three lines of therapy had failed.
They lived an average of 17.1 months despite the fact that two thirds of them had more than 20 tumors in their bones and lymph nodes.
Dr. Gisela Mautner, medical director of Noxopharm, said men “would normally have a much shorter survival expectation.”
“These provisional results are very relevant for a group of patients who are at the end of their treatment trip with a very limited life expectancy,” he said.
Twenty of the 32 patients had a strong reduction in their PSA levels, an important marker for anticancer activity, and many experienced a reduction in severe pain.
The study continues with another 24 men being treated with a higher dose of Veyonda, also in combination with 177Lu-PSMA-617, which is injected intravenously once every six weeks for 36 weeks.
Noxopharm says the suppository twice a day blocks cancer cells so they can’t repair DNA damaged by radiation therapy.
“We believe that Veyonda works in a way that will provide a valuable boost for all radiopharmaceuticals, not just 177Lu-PSMA-617,” said chief executive and chief executive, Dr. Graham Kelly.
At 1550 AEDT, Noxopharm shares rose one cent, or 4.4 percent, to 23.5 cents.